Mark Sullivan Biography and Net Worth

Insider of Definium Therapeutics

Mr. Sullivan is an experienced public company General Counsel and Corporate Secretary, with extensive expertise and demonstrated success in the areas of SEC reporting, financing, corporate governance and compliance, mergers and acquisitions, intellectual property, litigation management and business development. Prior to joining the Company, Mr. Sullivan was the General Counsel and Corporate Secretary of Sesen Bio, a biopharmaceutical company (prior to its merger with Carisma Therapeutics) (NASDAQ: CARM), from August 2019 to April 2023. Before that, he served as a private consultant to numerous life sciences companies. Previously, he served as the General Counsel, Chief Compliance Officer and Secretary of MModal Inc. (Nasdaq: MODL), formerly MedQuist, Inc., a leading healthcare IT company, until it was taken private by One Equity Partners, the private investment arm of JP Morgan Chase & Co. Prior to joining MModal, Mr. Sullivan was in private practice with Pepper Hamilton LLP and Drinker Biddle & Reath LLP. Mr. Sullivan received a B.A. from the University of Pennsylvania and a J.D. from the Rutgers University School of Law.

What is Mark Sullivan's net worth?: The estimated net worth of Mark Sullivan is at least $4.90 million as of December 26th, 2025. Mr. Sullivan owns 282,576 shares of Definium Therapeutics stock worth more than $4,902,694 as of February 10th. This net worth estimate does not reflect any other assets that Mr. Sullivan may own. Learn More about Mark Sullivan's net worth.
How old is Mark Sullivan?: Mr. Sullivan is currently 53 years old. There are 5 older executives and no younger executives at Definium Therapeutics. The oldest executive at Definium Therapeutics is Dr. Miriam Halperin Wernli B.A., M.A., M.B.A., MBA, Ph.D., Executive President, who is 71 years old. Learn More on Mark Sullivan's age.
How do I contact Mark Sullivan?: The corporate mailing address for Mr. Sullivan and other Definium Therapeutics executives is One World Trade Center Suite 8500 New York, NY 10007 United States. Definium Therapeutics can also be reached via phone at 212 220 6633 and via email at [email protected]. Learn More on Mark Sullivan's contact information.
Has Mark Sullivan been buying or selling shares of Definium Therapeutics?: Mark Sullivan has not been actively trading shares of Definium Therapeutics during the last quarter. Most recently, Mark Sullivan sold 11,276 shares of the business's stock in a transaction on Friday, December 26th. The shares were sold at an average price of $13.15, for a transaction totalling $148,279.40. Following the completion of the sale, the insider now directly owns 282,576 shares of the company's stock, valued at $3,715,874.40. Learn More on Mark Sullivan's trading history.
Who are Definium Therapeutics' active insiders?: Definium Therapeutics' insider roster includes Robert Barrow (Chief Executive Officer and Board Director), Schond Greenway (CFO), David Gryska (Director), Dan Karlin (Insider), Daniel Karlin (Insider), Carrie Liao (CAO), and Mark Sullivan (Insider). Learn More on Definium Therapeutics' active insiders.
Are insiders buying or selling shares of Definium Therapeutics?: During the last twelve months, insiders at the sold shares 12 times. They sold a total of 163,667 shares worth more than $1,515,041.22. The most recent insider tranaction occured on December, 26th when insider Daniel Karlin sold 5,600 shares worth more than $73,640.00. Insiders at Definium Therapeutics own 2.3% of the company. Learn More about insider trades at Definium Therapeutics.
Information on this page was last updated on 12/26/2025.

Mark Sullivan Insider Trading History at Definium Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/26/2025	Sell	11,276	$13.15	$148,279.40	282,576
9/25/2025	Sell	11,278	$9.77	$110,186.06	293,852
6/25/2025	Sell	11,491	$6.80	$78,138.80	305,130

Mark Sullivan Buying and Selling Activity at Definium Therapeutics

Definium Therapeutics Company Overview

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.

Today's Range

Now: $17.35

$16.55

$17.40

50 Day Range

MA: $14.38

$11.94

$18.23

2 Week Range

Now: $17.35

$4.70

$18.70

Volume

829,525 shs

Average Volume

1,992,820 shs

Market Capitalization

$1.71 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.57

Mark Sullivan Biography and Net Worth

What is Mark Sullivan's net worth?

How old is Mark Sullivan?

How do I contact Mark Sullivan?

Has Mark Sullivan been buying or selling shares of Definium Therapeutics?

Who are Definium Therapeutics' active insiders?

Are insiders buying or selling shares of Definium Therapeutics?